Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2012
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
2010
Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis
1989
Management of cancer pain
1999 Standout
Breast cancer
2016 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Small-Vessel Vasculitis
1997 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Gastrointestinal stromal tumour
2007
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Lung cancer: New biological insights and recent therapeutic advances
2011
Soft-Tissue Sarcomas in Adults
2005 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Strain‐Promoted Copper‐Free “Click” Chemistry for 18F Radiolabeling of Bombesin
2011 StandoutNobel
The Antiphospholipid Syndrome
2002 Standout
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Cutaneous Vasculitis: Its Relationship to Systemic Disease
1989
Breakthrough pain: characteristics and impact in patients with cancer pain
1999
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Atherosclerosis — An Inflammatory Disease
1999 Standout
Severe Adverse Cutaneous Reactions to Drugs
1994 Standout
Complement
2001 Standout
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
2011
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
2009
Activation of cultured vascular endothelial cells by antiphospholipid antibodies.
1995
The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro
1988
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
2005 StandoutNobel
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
2012
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Disorders Associated with Antibodies to Endothelial Cells
1989
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
2010
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
2012
VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site
1990 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Detection of endothelial cell‐reactive immunoglobulin in patients with anti‐phospholipid antibodies
1991
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
2000
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13).
1986
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Vascular damage in Wegener’s granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies
1991
Immunology and Clinical Importance of Antiphospholipid Antibodies
1991
Herpesviruses in Atherosclerosis and Thrombosis
1998
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon.
1986
Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA
1990
Synthesis and Characterization of Iodinated Tetrahydroquinolines Targeting the G Protein-Coupled Estrogen Receptor GPR30
2009
Warner-Lambert/Parke-Davis Award Lecture. Viral pathogenesis of atherosclerosis. Impact of molecular mimicry and viral genes.
1991
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites.
1988
Leukocyte-endothelial interactions
1985
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells
1989
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
2009
Direct One-Step18F-Labeling of Peptides via Nucleophilic Aromatic Substitution
2009
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
1989 StandoutScience
Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
1994 StandoutNobel
Metabolic reprogramming and cancer progression
2020 StandoutScience
The gene encoding the T-cell surface protein T4 is located on human chromosome 12.
1986 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Preleukemia and leukemia with 12p− and 19q+ chromosome alterations following alkeran therapy
1985
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Chemistry: Chemical con artists foil drug discovery
2014 StandoutNature
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
2013
Variable management of soft tissue sarcoma: Regional audit with implications for specialist care
1997
Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1.
1995
Immune Endothelial-Cell Injury in Heparin-Associated Thrombocytopenia
1987
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Complement Proteins C5b-9 Induce Secretion of High Molecular Weight Multimers of Endothelial von Willebrand Factor and Translocation of Granule Membrane Protein GMP-140 to the Cell Surface
1989
FDG-PET and Beyond: Molecular Breast Cancer Imaging
2005
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells
1984 Nature
Complement-mediated regulation of tissue factor activity in endothelium.
1995
Chemotherapy in Advanced Breast Carcinoma Comparison Between Doxorubicin-Cyclophosphamide and Cyclophosphamide-Methotrex-Ate-5-Fluorouracil-Vincristine-Prednisone
1985
Works of Alan P. Lyss being referenced
Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.
1991
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study
1999
Weekly, high‐dose paclitaxel in advanced lung carcinoma
2003
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.
1993
Chemotherapy of advanced breast cancer a general survey
1984
Carboplatin in non-small cell lung cancer: an update on the Cancer and Leukemia Group B experience.
1992
Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
2010
Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.
1984
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
2008
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
2015
Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.
2016
Fc and C3 Receptors Induced by Herpes Simplex Virus on Cultured Human Endothelial Cells
1982
Ph1-positive acute leukemia with a 17q;21q translocation
1984
Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival
2007
Management of soft tissue sarcomas of the extremities.
1991